LIVE POLIO IRUS VACCINES

Index
625
Poliomyelitis, paralytic-continued
results of laboratory investigation, 572
data compilation, 376
exposure, 203
incidence
by age, 552
by month and vaccination status, 467
changes in USSR, 493, 498
curves before and after vaccination, 429
dissemination, association with, 410
expected and observed differences in vaccinees,
397
47% in Salk vaccinees, Massachusetts, 374
high in infants, 270
in vaccinated areas, 394
Leopoldville, Congo, 1958 to 1960, 466
Nicaragua, 547-549
1960 was less than 5 year median, 455
reduction, Moscow, 422-424
southern Africa by race, 474
vaccinated and unvaccinated compared, 496
non-neurovirulent strains isolated, 201-202
not increased in contacts, 7
quality and quantity differences of virus, 228
Salk status of cases, 199, 436, 455, 459
seronegative index and hazard, 367
21 cases by start of vaccination program, 387
vaccine used to replace wild strains, 198
vaccination history confirmed, 554-559
Poliomyelitis virus
alteration in orally-excreted samples, 16
capacity to multiply outside CNS, 23
cold-mutants in humans, 101-108
displacement by compulsory immunization, 497
dissemination drop, 383
dominance after vaccination, 379
elution study, 43
evidence of recombination, 110
excretion during field trial, 439
mixtures of types, 114
high density animal viruses, 87
in radioactive phosphorus medium, 41
incidence compared with enteric viruses, 379
inhibitory material found in CNS, 86
invasion of CNS along peripheral nerves, 94
isolation and antibody response, 273, 320
isolation and monkey neurovirulence, 131
low neurovirulence in endemic periods, 50
mutation frequencies large, 109-110
mutations, low temperature, 101
properties of strains recovered, 431
purification
DEAE cellulose columns, 44
sewage sample study, 439
suppression by ECHO-1 isolate, 203
T tests and strains, 23, 66
Type 1
case, age and immunity status, 538
combination with grey matter, 49
elution off DEAE column, 43
from stools of healthy children, Louisiana, 101
infection during vaccination, 151
Type 1 continued
isolated,
Leopoldville, 47, 466, 469
Minnesota, 1960, 461
vaccinees, 540, 554
lack of immunity to, 477
responsible for majority of cases, 400
Type 1, Brunhilde, 229
Type 1, E206
bicarbonate study, 189
Type 1, Houston
antigenic marker study, 14
Type 1, Mahoney, 34, 118, 125-128, 287
avidity on cellulose resin, 41-43
elution, 44-46
lumbar cord after IS inoculation, 72
negative control, 55
serologic identification, 54-55
temperature marker test, 35. 65, 132
Type 1, Q-1 virus
first human passage of CHAT, 65
Type 1, R-1
isolated from vaccinee, growth curve patterns, 60,
62
Type 1, Sickle strain
temperature marker test, 65
TyDe 1, W-1
from asymptomatic case, Louisiana, 58-60
Type 1, W-3
from asymptomatic case, Louisiana, 59
Types 1 and 3
isolations, Philadelphia, 1959, 281
present before vaccination, 463
shift in Leopoldville, reason for, 469
Type 2
isolated from healthy-looking children, 191
virulent for monkeys, 474
Type 2, Jackson
serologic identification, 54
Type 2, Lansing
propagation in nonprimate host, 5, 192, 474
Type 2, MEF-1
decrease in virulence, 192-193
mouse selected derivative, 35
serologic identification, 54, 229
Type 2, SK-50
isolated in infant home in Tokyo, 191
Type 3
age and immunity status, 542
from healthy child, Cincinnati, 101
from vaccinated cases, 554
heterotypic Type 2 responses following exposure.
122
infection in Esthonian children's home, 431
intestinal resistance, 432
isolated, Massachusetts, 1959, 374
recurrent household episode, 148
Type 3, Fox
serologic identification, 54
Type 3, "Glenn"
cold muniitant IS, effect, 107
Type 3, H124
serologic identification, 54